{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":false},"limitationsAndCaveats":{"description":"On 04 November 2021, the study was terminated early during Phase 2a."},"pointOfContact":{"email":"trials@oncopeptides.com","organization":"Oncopeptides AB","phone":"+46 8 615 20 40","title":"VP Chief Operating Officer"}}